Shenzhen Hepalink Pharmaceutical Group Co
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., commonly known as Hepalink, is a leading global player in the pharmaceutical industry, headquartered in Shenzhen, China. Founded in 1998, the company has established itself as a prominent manufacturer and supplier of heparin and its derivatives, catering to both domestic and international markets. Hepalink's core offerings include active pharmaceutical ingredients (APIs) and finished dosage forms, with a strong emphasis on anticoagulant therapies. The company is renowned for its commitment to quality and innovation, which has positioned it as a trusted partner in the healthcare sector. With a robust presence in Europe, North America, and Asia, Hepalink continues to achieve significant milestones, including regulatory approvals and strategic partnerships, solidifying its reputation as a leader in the biopharmaceutical landscape.
DitchCarbon Score
How does Shenzhen Hepalink Pharmaceutical Group Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shenzhen Hepalink Pharmaceutical Group Co's score of 5 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Shenzhen Hepalink Pharmaceutical Group Co's reported carbon emissions
In 2023, Shenzhen Hepalink Pharmaceutical Group Co reported total carbon emissions of approximately 55,874,200 kg CO2e. This figure includes about 24,672,900 kg CO2e from Scope 1 emissions and approximately 31,201,200 kg CO2e from Scope 2 emissions. Comparatively, in 2022, the company recorded total emissions of about 58,349,400 kg CO2e, with Scope 1 emissions at approximately 24,355,200 kg CO2e and Scope 2 emissions at around 33,994,200 kg CO2e. This indicates a reduction in total emissions from 2022 to 2023. In 2021, the total emissions were about 65,879,600 kg CO2e, comprising approximately 25,352,500 kg CO2e from Scope 1 and about 40,527,100 kg CO2e from Scope 2. Despite these reductions, Shenzhen Hepalink has not publicly disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or any formal climate pledges. The company continues to monitor and report its emissions, reflecting a commitment to transparency in its climate impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 25,352,500 | 00,000,000 | 00,000,000 |
| Scope 2 | 40,527,100 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Shenzhen Hepalink Pharmaceutical Group Co is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
